Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StockCall Pre-Market Review on BMY, LLY, ENDP, and AGN

BMY, LLY
StockCall Pre-Market Review on BMY, LLY, ENDP, and AGN

StockCall.com Provides Stock Research on Bristol-Myers Squibb Co., Eli Lilly & Co., Endo Pharmaceuticals Holdings Inc., and Allergan Inc.

New York City, New York -- (June 05, 2013)

Drug manufacturers in the U.S. as well as globally have been facing increasing competition from generic drug makers following the expiration of patents on several blockbuster drugs. This year alone patents on drugs with annual sales of nearly $30 billion are set to expire. The “patent cliff” is expected to have a significant impact on top-line of major drug manufacturers. Several drug manufacturers have boosted their research and development activities in order to offset the revenue loss from patent cliff. On Tuesday, June 4, 2013, shares in drug manufacturers ended mostly lower as the broad market slipped. The major movers in the sector included Bristol Myers Squibb Co. (NYSE: BMY), Eli Lilly & Co. (NYSE: LLY), Endo Health Solutions Inc. (NASDAQ: ENDP), and Allergan Inc. (NYSE: AGN). StockCall analysts initiated preliminary technical research on BMY, LLY, ENDP, and AGN. These free reports are accessible by signing today at

www.stockcall.com/register

Shares in Bristol Myers Squibb Co. fell sharply on Tuesday, tracking losses in the broader market. The company’s shares traded between $46.40 and $48.18 before finishing the day 1.60% lower at $46.83. A total of 21.51 million shares were traded which is significantly above the daily average volume of 12.33 million. However, despite the sharp decline yesterday, the stock is still up nearly 46.50% so far this year. The stock is currently trading over 5.50% below its 52-week high. Shares of BMY are currently trading well above their 50- and 200-day moving averages. The free technical analysis on BMY is available by signing up at

www.StockCall.com/BMY060513.pdf

Eli Lilly & Co.’s stock moved lower in the last session extending its losses from its previous sessions. The company’s shares traded between $52.22 and $53.42 before finishing the day 1.20% lower at $52.50. A total of 4.09 million shares were traded which is well below the daily average volume of 5.74 million. The stock has now fallen nearly 3% in the last three sessions. However, despite the recent losses, the stock is still up nearly 8.40% so far in 2013. The stock is currently trading 9.31% below its 52-week high. Register now to download the free research on LLY at

www.StockCall.com/LLY060513.pdf

Shares in Endo Health Solutions Inc. slipped yesterday, reversing some of its gains from previous trading sessions. The company’s shares ended the day 0.74% lower at $36.46 after trading between $36.15 and $36.97. Volume was at 994,246 shares, which is well below the daily average volume of 2.45 million. However, despite the pullback on Tuesday, shares of ENDP have grown nearly 1.50% in the last three sessions. The stock is currently trading close to its 52-week high of $38.32. Free report on ENDP can be accessed by registering at

www.StockCall.com/ENDP060513.pdf

Allergan Inc.’s stock also moved lower on Tuesday, extending its losses from previous sessions. The company’s shares hit an intraday low of $98 before finishing the day 0.48% lower at $98.47. A total of 1.46 million shares were traded which is well below the daily average volume of 2.83 million. The company’s shares have now fallen nearly 2.60% in the last three sessions. The stock is currently trading 15.40% below its 52-week high. Shares of AGN are also trading below their 50- and 200-day moving averages.Register withStockCall and download the research on AGN for free at

www.StockCall.com/AGN060513.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

www.stockcall.com

Contact Person:

William T. Knight

Email: info@stockcall.com

Contact Number: (646) 396-9857 (9:00 am EST – 01:30 pm EST)



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today